MedTech Spectrum

Article Name Artificial Intelligence

RIVANNA Secures $30.5M from BARDA to Advance Accuro XV Musculoskeletal Imaging

Accuro XV integrates ultrasound-based bone and 3D soft-tissue imaging technology with AI-enabled software.

28th July, 2023

ConcertAI's TeraRecon Partners with ClariPi for AI-Enabled Medical Imaging on Eureka Platform

- Advanced visualization and AI leader TeraRecon, a ConcertAI company, announced a strategic partnership with ClariPi, an innovative medical imaging AI company, to integrate ClariPi's solutions into its Eureka platform. With this partnership, TeraRecon continues to expand its offerings to enhance clinical workflows, delivering comprehensive medical imaging AI solutions to customers worldwide.

28th July, 2023

Korean startup Lunit accelerates expansion across Middle East with new supply contract

Supplying AI-powered breast screening solution to Dr. Sulaiman Al Habib Medical Group for the next three years

27th July, 2023

Japan produces world's first report on brain activation by Plasmacluster Technology

Validation of the mechanism of its enhancing effect on human work performance by measuring brain function

27th July, 2023

Medlinker's MedGPT Performs 96% As Well As Top Human Doctors

In a Livestreamed Real-World Assessment, MedGPT's AI Doctors Rival Diagnostic Accuracy of China's Leading Doctors

24th July, 2023

Lark Health and Desert Oasis Healthcare Announce Expanded Partnership

Lark Health, the leading AI-powered digital care coaching company for the prevention and management of chronic conditions, and Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, today announced their expanded partnership where DOHC will offer Lark's Prevention program and CDC-recognized Diabetes Prevention program to their patients.

21st July, 2023

Verantos' AI Advancement in Neurology Bolstered by Groundbreaking Migraine Real-World Evidence

Technology enables inference of subjective outcomes from routinely collected data

20th July, 2023

Astellas and Eko Health Partner to Integrate Eko CORE 500™ Stethoscope into Z1608 for Heart Failure Patients

Transforming Heart Failure Management: Astellas, Eko Health & Welldoc Collaborate

19th July, 2023

Optina's REPHRASE Study Validates Innovative Alzheimer's Test

Optina Diagnostics' pioneering pivotal REPHRASE study, currently underway, is poised to revolutionize the diagnosis and management of Alzheimer's Disease (AD). This landmark study is focused on validating the novel awAIr™-Cerebral Amyloid Status (CAS) test, an innovative tool intended to provide physicians with definitive information about Alzheimer's pathology, enabling improved management of cognitive impairments.

18th July, 2023

DiamiR Biosciences Partners with JADBio to Utilize Machine Learning in Assay Development

DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into an agreement with JADBio to utilize its Automated Machine Learning (AutoML) Platform and Services for development of predictive models based on DiamiR's microRNA panels and other factors for risk assessment in Alzheimer's disease and Rett syndrome.

10th July, 2023

CMS Introduces HCPCS Code for Ultromics EchoGo® Heart Failure, Enhancing HFpEF Detection Access

Ultromics, a leading health technology company advancing a novel approach for detecting heart failure and its phenotypes, announced today the assignment of a new outpatient code by the Centers for Medicare and Medicaid Services (CMS), for its flagship product, EchoGo® Heart Failure. HCPCS code C9786 can now be used for billing artificial intelligence to aid the detection of Heart Failure with Preserved Ejection Fraction (HFpEF). HCPCS code C9786 can now be used for billing artificial intelligence to aid the detection of Heart Failure with Preserved Ejection Fraction (HFpEF).

06th July, 2023

Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker

Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. With more than 80% of people who need a pacemaker requiring pacing in two chambers of the heart (both the right atrium and right ventricle), the approval significantly increases access to leadless pacing for millions of people across the U.S.[i]

06th July, 2023

AOI Revolutionizes Cancer Care in Telangana with AI-Powered Ethos Radiotherapy, Becomes Advanced Cancer Centre

Inaugurated by the Minister for Finance, Health, Medical & Family Welfare, Government of Telangana

05th July, 2023

Lunit's AI Solution Impacts Radiologists' Lung Cancer Diagnosis

Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists' chest X-ray analysis performance

04th July, 2023

SimonMed Imaging Implements 3rd Generation iCAD Breast AI 3.0

At no additional cost to patients

03rd July, 2023

Kauvery Hospital, Chennai Introduces Next-Generation AI-Based Ultreon Coronary Imaging System

Kauvery Heart Institute, the center of excellence in comprehensive cardiac services at Kauvery Hospital - Radial Road, Kovilambakkam, proudly announces the launch of the latest AI-based Ultreon Coronary Imaging system. By acquiring this ground-breaking technology, Kauvery Hospital - Radial Road positions itself as the leader in Cardiac Sciences by being the first hospital in Tamil Nadu to acquire a state-of-the-art OCT system, empowering cardiologists with advanced capabilities for precise coronary analysis and guiding complex angioplasty and stenting procedures.

30th June, 2023

Koning Corporation Unveils Revolutionary AI-Enhanced Software to Boost Breast CT Image Quality

Koning Corporation, a global leader in breast computed tomography (CT) technology, is thrilled to announce the launch of its breakthrough Artificial Intelligence (AI) software, designed to enhance image quality significantly. The upgrade to their software system is set to provide unparalleled clarity in breast imaging, promising a game-changing impact on the early detection and treatment of breast cancer.

28th June, 2023

Roche Gets FDA Clearance for Additional Alzheimer's CSF Assays, Enhancing Diagnosis and Treatment Decisions

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and tTau assays (used as a tTau/Abeta42 ratio) measure two biomarkers of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease.

28th June, 2023